» Articles » PMID: 30652485

Gender Difference in Damage-Mediated Signaling Contributes to Pulmonary Arterial Hypertension

Overview
Specialty Endocrinology
Date 2019 Jan 18
PMID 30652485
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary arterial hypertension (PAH) is a progressive lethal disease with a known gender dimorphism. Female patients are more susceptible to PAH, whereas male patients have a lower survival rate. Initial pulmonary vascular damage plays an important role in PAH pathogenesis. Therefore, this study aimed at investigating the role of gender in activation of apoptosis/necrosis-mediated signaling pathways in PAH. The media collected from pulmonary artery endothelial cells (PAECs) that died by necrosis or apoptosis were used to treat naive PAECs. Necrotic cell death stimulated phosphorylation of toll-like receptor 4, accumulation of interleukin 1 beta, and expression of E-selectin in a redox-dependent manner; apoptosis did not induce any of these effects. In the animal model of severe PAH, the necrotic marker, high mobility group box 1 (HMGB1), was visualized in the pulmonary vascular wall of male but not female rats. This vascular necrosis was associated with male-specific redox changes in plasma, activation of the same inflammatory signaling pathway seen in response to necrosis , and an increased endothelial-leukocyte adhesion in small pulmonary arteries. In PAH patients, gender-specific changes in redox homeostasis correlated with the prognostic marker, B-type natriuretic peptide. Males had also shown elevated circulating levels of HMGB1 and pro-inflammatory changes. This study discovered the role of gender in the initiation of damage-associated signaling in PAH and highlights the importance of the gender-specific approach in PAH therapy. In PAH, the necrotic cell death is augmented in male patients compared with female patients. Factors released from necrotic cells could alter redox homeostasis and stimulate inflammatory signaling pathways.

Citing Articles

Mechanisms of lung endothelial cell injury and survival in pulmonary arterial hypertension.

Marinho Y, Villarreal E, Loya O, Oliveira S Am J Physiol Lung Cell Mol Physiol. 2024; 327(6):L972-L983.

PMID: 39406383 PMC: 11684956. DOI: 10.1152/ajplung.00208.2024.


Prenatal Sildenafil and Fetal-placental Programming in Human Pregnancies Complicated by Fetal Growth Restriction: A Retrospective Gene Expression Analysis.

Terstappen F, Plosch T, Calis J, Ganzevoort W, Pels A, Paauw N J Trial Error. 2024; :e16.

PMID: 39404670 PMC: 7616564. DOI: 10.36850/e16.


EnFUSiasm for Healing: Ultrasound Neuromodulation in PAH.

Rafikova O, James J, Kudryashova T Circ Res. 2024; 135(1):57-59.

PMID: 38900858 PMC: 11192238. DOI: 10.1161/CIRCRESAHA.124.324791.


The association between sex and neonatal respiratory distress syndrome.

Fang K, Yue S, Wang S, Wang M, Yu X, Ding Y BMC Pediatr. 2024; 24(1):129.

PMID: 38373935 PMC: 10875892. DOI: 10.1186/s12887-024-04596-3.


Human Resistin Induces Cardiac Dysfunction in Pulmonary Hypertension.

Lin Q, Kumar S, Kariyawasam U, Yang X, Yang W, Skinner J J Am Heart Assoc. 2023; 12(6):e027621.

PMID: 36927008 PMC: 10111547. DOI: 10.1161/JAHA.122.027621.


References
1.
Bianchi M, Manfredi A . Chromatin and cell death. Biochim Biophys Acta. 2004; 1677(1-3):181-6. DOI: 10.1016/j.bbaexp.2003.10.017. View

2.
Abe K, Toba M, Alzoubi A, Ito M, Fagan K, Cool C . Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010; 121(25):2747-54. DOI: 10.1161/CIRCULATIONAHA.109.927681. View

3.
Casserly B, Klinger J . Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther. 2010; 3:269-87. PMC: 2802126. DOI: 10.2147/dddt.s4805. View

4.
Carta S, Castellani P, Delfino L, Tassi S, Vene R, Rubartelli A . DAMPs and inflammatory processes: the role of redox in the different outcomes. J Leukoc Biol. 2009; 86(3):549-55. DOI: 10.1189/jlb.1008598. View

5.
de Jesus Perez V . Making sense of the estrogen paradox in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011; 184(6):629-30. DOI: 10.1164/rccm.201107-1184ED. View